ELI Radiopharma and HTA Announce Strategic Collaboration to Advance Radiopharmaceutical Innovation

Eli Radiopharma and HTA Co., Ltd. (HTA) have entered into a strategic collaboration to jointly advance innovation and establish a new ecosystem within the radiopharmaceutical industry.

By integrating Eli Radiopharma's expertise in early-stage R&D with HTA's end-to-end supply chain capabilities, the partnership will operate under an exclusively joint development model of benefit and risk sharing for pipeline advancement. Under the agreement, Eli Radiopharma will be entitled to receive millions of milestone payments upon reaching clinical achievements, as well as future market benefits on a net sales basis. The two parties aim to foster synergies, accelerate the translation of scientific breakthroughs, and drive the high-quality development of radiopharmaceuticals to bring better solutions to patients.